ArticleESMO open2018

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.

Kathleen N Moore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.